Literature DB >> 7582482

Polydeoxyribonucleotides and nitric oxide release from guinea-pig hearts during ischaemia and reperfusion.

E Masini1, M Lupini, L Mugnai, S Raspanti, P F Mannaioni.   

Abstract

1. Two polydeoxyribonucleotides, produced by the controlled hydrolysis of DNA of mammalian lung (defibrotide and its lower molecular weight fraction, P.O. 085 DV), were studied for their ability to modify the release of nitrite and the coronary flow in perfusates collected from isolated, normally perfused hearts of guinea-pigs and from hearts subjected to regional ischaemia and reperfusion. 2. In guinea-pig normally perfused hearts, both defibrotide (DFT) and its fraction, P.O. 085 DV, increase the amount of nitrite appearing in perfusates in a concentration-dependent fashion. At the highest concentration studied (10(-6) M), P.O. 085 DV was more effective than DFT. A concomitant increase in the coronary flow was observed. 3. The increase in nitrite in perfusates and the increase in coronary flow induced by both DFT and P.O. 085 DV were significantly reduced by NG-monomethyl-L-arginine (L-NMMA, 10(-4) M), an inhibitor of nitric oxide synthase (NOS). 4. The endothelium-dependent vasodilator, acetylcholine (ACh), enhances the formation of nitrite and the coronary flow. Both the increase in coronary flow and in the formation of nitrite were significantly reduced by L-NMMA (10(-4) M). 5. In guinea-pig hearts subjected to ischaemia and reperfusion, the effect of both compounds in increasing the amount of nitrite in perfusates was more evident and more pronounced with P.O. 085 DV. 6. Reperfusion-induced arrhythmias were significantly reduced by both compounds to the extent of complete protection afforded by compound P.O. 085 DV. 7. The cardioprotective and antiarrhythmic effects of DFT and P.O. 085 DV are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582482      PMCID: PMC1908494          DOI: 10.1111/j.1476-5381.1995.tb14978.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

Review 1.  Histamine and cardiac arrhythmias.

Authors:  A A Wolff; R Levi
Journal:  Circ Res       Date:  1986-01       Impact factor: 17.367

2.  Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia.

Authors:  A M Lefer; M L Ogletree; J B Smith; M J Silver; K C Nicolaou; W E Barnette; G P Gasic
Journal:  Science       Date:  1978-04-07       Impact factor: 47.728

3.  Effect of coronary perfusion rate on the hydrolysis of exogenous and endogenous acetylcholine in the isolated heart.

Authors:  H A Dieterich; K Löffelholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-01       Impact factor: 3.000

Review 4.  Histamine release in clinical conditions.

Authors:  W Lorenz; A Doenicke
Journal:  Mt Sinai J Med       Date:  1978 May-Jun

5.  Usefulness of defibrotide in protecting ischemic myocardium from early reperfusion damage.

Authors:  C Thiemermann; P Löbel; K Schrör
Journal:  Am J Cardiol       Date:  1985-12-01       Impact factor: 2.778

6.  Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation.

Authors:  P J Simpson; S E Mitsos; A Ventura; K P Gallagher; J C Fantone; G D Abrams; M A Schork; B R Lucchesi
Journal:  Am Heart J       Date:  1987-01       Impact factor: 4.749

7.  Defibrotide protects rabbit myocardium from ischemia: relationship with the eicosanoid system.

Authors:  F Berti; G Rossini; C Omini; L Daffonchio; C Tondo; G Cali
Journal:  Pol J Pharmacol Pharm       Date:  1987 Sep-Oct

8.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

9.  Generation of nitric oxide from nitrovasodilators modulates the release of histamine from mast cells.

Authors:  E Masini; M G Di Bello; A Pistelli; S Raspanti; F Gambassi; L Mugnai; M Lupini; P F Mannaioni
Journal:  J Physiol Pharmacol       Date:  1994-03       Impact factor: 3.011

10.  Prostacyclin-thromboxane interactions in the platelet-perfused in vitro heart.

Authors:  K Schrör; P Köhler; M Müller; B A Peskar; P Rösen
Journal:  Am J Physiol       Date:  1981-07
View more
  8 in total

1.  What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance.

Authors:  Marta Palomo; Enrique Mir; Montse Rovira; Ginés Escolar; Enric Carreras; Maribel Diaz-Ricart
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

2.  Possible role of cardiac mast cell degranulation and preservation of nitric oxide release in isolated rat heart subjected to ischaemic preconditioning.

Authors:  V Parikh; M Singh
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

Review 3.  The use of defibrotide in blood and marrow transplantation.

Authors:  Paul G Richardson; Enric Carreras; Massimo Iacobelli; Bijan Nejadnik
Journal:  Blood Adv       Date:  2018-06-26

Review 4.  Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Authors:  J Khosla; A C Yeh; T R Spitzer; B R Dey
Journal:  Bone Marrow Transplant       Date:  2017-10-02       Impact factor: 5.483

5.  Cardioprotective actions of oligotide, a single stranded polydeoxyribonucleotide complex, in myocardial ischaemia and reperfusion injury.

Authors:  T Murohara; M Buerke; A M Lefer
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  Haeme oxygenase-1 and cardiac anaphylaxis.

Authors:  J F Ndisang; R Wang; A Vannacci; C Marzocca; O Fantappiè; R Mazzanti; P F Mannaioni; E Masini
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

7.  EPR detection of endogenous nitric oxide in postischemic heart using lipid and aqueous-soluble dithiocarbamate-iron complexes.

Authors:  A M Komarov; J H Kramer; I T Mak; W B Weglicki
Journal:  Mol Cell Biochem       Date:  1997-10       Impact factor: 3.396

Review 8.  Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.

Authors:  Gillian M Keating
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.